Biogen (BIIB) Invested Capital (2009 - 2026)

Biogen (BIIB) has reported Invested Capital for 18 consecutive years, with $24.9 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Invested Capital rose 15.85% year-over-year to $24.9 billion; the TTM figure through Mar 2026 stood at $24.9 billion (up 15.85% YoY), while the FY2025 annual figure was $24.5 billion, up 15.43% from the prior year.
• Invested Capital came in at $24.9 billion for Q1 2026 at Biogen, up from $24.5 billion in the prior quarter.
• The five-year high for Invested Capital was $24.9 billion in Q1 2026, with the low at $6.3 billion in Q3 2025.
• Average Invested Capital over 5 years is $20.3 billion, with a median of $21.3 billion recorded in 2024.
• Across the five-year window, Invested Capital plunged 69.69% in 2025 and rose 15.85% in 2026, its largest moves.
• Year by year, Invested Capital stood at $19.7 billion in 2022, then increased by 9.75% to $21.6 billion in 2023, then declined by 1.5% to $21.3 billion in 2024, then climbed by 15.43% to $24.5 billion in 2025, then grew by 1.62% to $24.9 billion in 2026.
• According to Business Quant data, Invested Capital over the past three periods registered $24.9 billion, $24.5 billion, and $6.3 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.